Mastectomy for Breast Cancer: 631 Real Stories

631 stories match breast cancer and mastectomy. 611 of them mention surgery.

Cancer Stories

Kim, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer Alliance
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage 2 triple-negative breast cancer: pathologic complete response to chemotherapy

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: Triple-negative breast cancer, with pathogenic PALB2 c.1451T>A variant found in blood/buccal/tumor testing.

As of May 2024, more than 1 year after surgery, she was well and free of cancer after neoadjuvant chemotherapy, mastectomy, reconstruction, and preventive adnexectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 50%; tumor-infiltrating lymphocytes 60%

As of May 2024, 6 months after mastectomy and adjuvant radiotherapy for pT2N0M0 triple-negative secretory breast cancer, clinical examination and imaging showed no evidence of relapse.

PubMed Central
OutcomeCancer-Free / NED
Melissa, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Stage IV Invasive Lobular Carcinoma: Melissa's Patient Story

Patient Info: Melissa Adams, Female | Stage IV

Melissa’s breast cancer progressed after maintenance hormone therapy and was reassigned as Stage IV. She describes living with incurable disease while focusing on keeping the cancer at bay and staying engaged with family, church, and advocacy.

AACR
OutcomeLiving With Cancer
Irasema, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Irasema's Survivor Story

Patient Info: Irasema Partida Chavez, Female

Biomarkers: HER2-positive

Irasema reported no evidence of breast cancer for 3 years after surgery and HER2-targeted treatment.

AACR
OutcomeCancer-Free / NED
Katrece, who was diagnosed with Stage III Inflammatory Breast CancerBreast Cancer

Stage III Inflammatory Breast Cancer: Katrece's Patient Story

Patient Info: Katrece Nolen, Female | Stage III

More than 10 years after her diagnosis, Katrece was taking medication intended to reduce recurrence risk and remained active in advocacy for people with inflammatory breast cancer.

AACR
OutcomeNot reported
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative metaplastic breast cancer with complete pathologic response to chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 <10%; CK-positive; S100-positive; focal vimentin-positive

At 1-year follow-up, there were no signs of recurrence after doxorubicin/cyclophosphamide chemotherapy and modified radical mastectomy with complete pathologic response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Freezing treatment (cryoablation) used to manage slow-growing triple-negative breast cancer

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; androgen receptor-positive in original tumor; Ki-67 5% initially and 10% at recurrence

At 29 months after recurrence diagnosis and 20 months after the first cryoablation, no viable breast tumor was seen at treated sites, axillary nodes were unchanged, pain was absent, and she remained active and independent.

PubMed Central
OutcomeStable
Allison, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient Story
OutcomeCare Ongoing
Harvey, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III Invasive Lobular Carcinoma: Harvey's Patient Story

Patient Info: Harvey, Male, 50s | Stage III

Biomarkers: Genetic testing negative

Harvey was in active treatment for male Stage IIIC grade 3 ILC after right mastectomy and initiation of AC-T chemotherapy, with radiation and endocrine/targeted therapy planned as of March 2024.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
SI
Breast Cancer

Stage II Triple-Negative Breast Cancer: Chance's Survivor Story

Patient Info: Chance Osborne, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of March 2024, Chance Osborne was a young Stage II TNBC survivor with a BRCA1 mutation, sharing her experience with chemotherapy, double mastectomy recovery, and advocacy.

Dear Cancer, I'm Beautiful (LBBC)
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Rare soft-tissue sarcoma of the breast

Patient Info: Anonymized, Female | Stage IV

Biomarkers: TLE1 strongly and diffusely positive; p63, CK7

Metastatic Site: lungs

After mastectomy, the cancer was metastatic to the lungs and care was palliative.

PubMed Central
OutcomeLiving With Cancer
Debbie, who was diagnosed with Stage I Breast AdenocarcinomaBreast Cancer

Stage I Breast Adenocarcinoma: Debbie's Survivor Story

Patient Info: Debbie Wade, Female | Stage I

As of February 2024, Debbie was cancer-free after double mastectomy, 4 weeks of radiation therapy and DIEP flap reconstruction for Stage I mucinous adenocarcinoma of the left breast, with mild left-arm lymphedema as the only reported side effect.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Male Invasive Lobular Breast Cancer With a Pathogenic PALB2 Variant

Patient Info: Anonymized, male, 40s

Biomarkers: ER-positive; PR-positive; HER2 not amplified; pathogenic PALB2 variant

He was disease-free at 1-year follow-up after mastectomy, chemotherapy, and radiotherapy.

PubMed Central
OutcomeCancer-Free / NED
Sally, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Sally's Survivor Story

Patient Info: Sally Johnston, 70+

Biomarkers: Estrogen receptor-positive

Sally was in remission by the end of 2014 and remained active about 10 years after treatment.

Dana-Farber
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Aggressive breast cancer presenting with severe skin infection

Patient Info: Anonymized, Female

Biomarkers: ER 99% positive; PR 99% positive; HER2 1+ / negative; Ki-67 3%; grade 2; 3 interpectoral lymph nodes negative; later axillary-node biopsy benign

She recovered from sepsis and surgery, had no distant metastases and a benign axillary-node biopsy, and was receiving adjuvant radiation with anastrozole ongoing.

PubMed Central
OutcomeCare Ongoing